Last week, IMMUTOL partners gathered in Barcelona for the 1st Annual Meeting of the IMMUTOL project (6-7 June) to celebrate the progress of this European Union funded project. Asphalion, in charge of the regulatory activities, presented a summary of the regulatory road map (deliverable 6.1) within WP6. Preliminary results from partners were presented, and a roundtable on the hot topic of target patient selection guided the project’s progression through the 2nd year.
IMMUTOL’s objective is to pave the way for new tolerogenic cell-based therapies to cure/reverse several autoimmune conditions, developing a more potent and durable treatment for autoimmune diseases with an unmet medical need, particularly Multiple Sclerosis.
Multiple Sclerosis is a chronic inflammatory demyelinating disease of the central nervous system. In Europe alone, there are around 500,000 people suffering from this disease, which is often diagnosed in individuals (mostly women) aged 20 to 40. With increasing disability, this incurable disease greatly reduces the quality of life for patients and imposes a high burden on society in terms of the cost of therapy and chronic need for care.
The IMMUTOL consortium gathers experts and institutions from different sectors, including research institutions, academia, patients’ associations, hospitals, and corporate SMEs.
Check out the IMMUTOL website for more information on the project. For further information or regulatory support for your HORIZON project, contact us at [email protected].
